Association of statin and nonsteroidal anti-inflammatory drug use with prostate cancer outcomes: Results from CaPSURE

BJU International

Volumn 106, Issue 5, 2010, Pages 627-632

  Katz, Matthew S ^a,b   Carroll, Peter R ^c,d   Cowan, Janet E ^d   Chan, June M ^d,e   D'Amico, Anthony V ^f,g  

^a Radiation Oncology Associates PA   (United States)

^b Saints Medical Center   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

all cause mortality; NSAID; prostate cancer; prostatectomy; radiotherapy; statin

Indexed keywords

ANTIANDROGEN; ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NONSTEROID ANTIINFLAMMATORY AGENT; PRAVASTATIN; PROSTAGLANDIN SYNTHASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; COMORBIDITY; DRUG USE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; RISK REDUCTION;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHEMOTHERAPY, ADJUVANT; EPIDEMIOLOGIC METHODS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROSTATECTOMY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; UNITED STATES;

EID: 77955881529     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09232.x     Document Type: Article

References (26)

1. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003 326 : 1407 8
2. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005 366 : 1267 78
3. Afilalo J, Duque G, Steele R et al. Statins for secondary prevention in elderly patients: a hierarchical Bayesian meta-analysis. J Am Coll Cardiol 2008 51 : 37 45
4. Wong WW, Dimitroulakos J, Minden MD et al. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002 16 : 508 19
5. Splichal JE, Stamm JA, Ornstein DL. The statins: multifunctional antithrombotic and antineoplastic drugs. Semin Thromb Hemost 2003 29 : 259 74
6. Katz MS. Therapy insight: potential of statins for cancer chemoprevention and therapy. Nat Clin Pract Oncol 2005 2 : 82 9
7. Platz EA, Leitzmann MF, Visvanathan K et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006 98 : 1819 25
8. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002 94 : 252 6
9. Chan JM, Feraco A, Shuman M et al. The epidemiology of prostate cancer - with a focus on nonsteroidal anti-inflammatory drugs. Hematol Oncol Clin North Am 2006 20 : 797 809
10. Platz EA, Rohrmann S, Pearson JD et al. Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol Biomarkers Prev 2005 14 : 390 6
11. Albertsen PC, Fryback DG, Storer BE et al. The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 1996 156 : 127 32
12. Fowler JE Jr., Terrell FL, Renfroe DL. Co-morbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy. J Urol 1996 156 : 1714 8
13. Newschaffer CJ, Otani K, McDonald MK et al. Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J Natl Cancer Inst 2000 92 : 613 21
14. Gleason DF. Histologic grading and clinical staging of prostatic carcinoma. In Tannenbaum M ed. Urologic Pathology: the Prostate
15. Marr PL, Elkin EP, Arredondo SA et al. Comorbidity and primary treatment for localized prostate cancer: data from CaPSURE. J Urol 2006 175 : 1326 31
16. DÍAmico AV, Whittingon R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998 280 : 969 74
17. Allison PD. Survival Analysis Using the SAS System: A Practical Guide.
18. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972 34 : 187 220
19. Cyrus-David MS, Weinberg A, Thompson T et al. The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report. J Urol 2005 173 : 1923 5
20. Chism DB, Hanlon AL, Troncoso P et al. The Gleason score shift: score four and seven years ago. Int J Radiat Oncol Biol Phys 2003 56 : 1241 7
21. Albertsen PC, Hanley JA, Barrows GH et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 2005 97 : 1248 53
22. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase-2. JAMA 2006 296 : 1633 44
23. Johnsen SP, Larsson H, Tarone RE et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 2005 165 : 978 84
24. Kimmel SE, Berlin JA, Reilly M et al. The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. J Am Coll Cardiol 2004 43 : 985 90
25. Ilkhanoff L, Lewis JD, Hennessy S et al. Potential limitations of electronic database studies of prescription non-aspirin non-steroidal anti-inflammatory drugs (NANSAIDs) and risk of myocardial infarction (MI). Pharmacoepidemiol Drug Saf 2005 14 : 513 22
26. Feuer EJ, Merrill RM, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer ñ II: cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst 1999 91 : 1025 32